儿童肾移植受者年龄相关差异:排斥率、感染与他克莫司暴露
基于CERTAIN注册研究802例儿童肾移植受者的分析显示,婴儿及年幼儿童感染发生率和住院天数显著高于青少年,而青少年移植后第一年活检证实的急性排斥率显著更高。婴儿及年幼儿童他克莫司谷浓度和浓度剂量比更低、个体间变异更高,提示应依据年龄特异性风险制定个体化免疫抑制方案。
要点
- 婴儿及年幼儿童感染风险及住院负担显著高于青少年
- 青少年移植后第一年活检证实的急性排斥率显著更高
- 婴儿及年幼儿童他克莫司暴露更低、清除更高且个体间变异更大
核心结论
- 儿童肾移植受者在他克莫司为基础的免疫抑制方案下,排斥率、感染事件及他克莫司暴露和清除存在重要年龄相关差异,提示应基于年龄特异性风险个体化免疫抑制治疗。
研究设计与样本
- 对CERTAIN注册研究802例儿童肾移植受者进行大规模分析,来自14个国家40个中心,纳入标准为他克莫司为基础免疫抑制方案且随访至少2年。
- 患者按年龄分为3组:婴儿及年幼儿童(<6岁)、学龄儿童(6-12岁)和青少年(>12岁),以评估结局的年龄相关差异。
主要发现
- 中位随访48个月(IQR 36-72)。
- 移植后2年内,婴儿及年幼儿童感染发生率显著高于青少年(80.6% vs 55.0%,P < 0.001),累积住院天数中位数显著更高(13天 vs 7天,P < 0.001)。
- 青少年移植后第一年活检证实的急性排斥率显著高于婴儿及年幼儿童(21.7% vs 12.6%,P = 0.007)。
- 婴儿及年幼儿童他克莫司谷浓度、浓度剂量比(C/D)显著低于青少年,而他克莫司个体间变异(TacIPV)显著更高(均P < 0.01)。
临床怎么用
- 对婴儿及年幼儿童应关注感染预防和住院负担,对青少年应加强排斥监测。
- 他克莫司暴露和清除的年龄差异提示需按年龄调整剂量和监测谷浓度。
- 该数据可作为未来新型免疫抑制药物研究的基准。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Data on age-related differences in rejection rates, infectious episodes, and tacrolimus exposure in pediatric kidney transplant recipients (pKTRs) on a tacrolimus-based immunosuppressive regimen are scarce. METHODS: We performed a large-scale analysis of 802 pKTRs from the Cooperative European Paediatric Renal Transplant Initiative (CERTAIN) registry from 40 centers in 14 countries. The inclusion criteria were a tacrolimus-based immunosuppressive regimen and at least 2 years of follow-up. The patient population was divided into 3 age groups (infants and young children aged <6 years, school-aged children 6-12 years, and adolescents aged >12 years) to assess age-related differences in outcome. RESULTS: Median follow-up was 48 months (interquartile range [IQR], 36-72). Within the first 2 years posttransplant, infants, and young children had a significantly higher incidence of infections (80.6% vs. 55.0% in adolescents, P < 0.001) and a significantly higher number of cumulative hospital days (median 13 days vs. 7 days in adolescents, P < 0.001). Adolescents had a significantly higher rate of biopsy-proven acute rejection episodes in the first-year posttransplant (21.7%) than infants and young children (12.6%, P = 0.007). Infants and young children had significantly lower tacrolimus trough levels, lower tacrolimus concentration-to-dose (C/D) ratios as an approximation for higher tacrolimus clearance, and higher tacrolimus interpatient variability (TacIPV) (all P < 0.01) than adolescents. CONCLUSION: This is the largest study to date in European pKTRs on a tacrolimus-based immunosuppressive regimen, and it shows important age-related differences in rejection rates, infection episodes, as well as tacrolimus exposure and clearance. This data suggests that immunosuppressive therapy in pKTRs should be tailored and personalized according to the age-specific risk profiles of this heterogeneous patient population. The data may serve as a benchmark for future studies with novel immunosuppressive drugs.
引用
- Baghai Arassi M, Feißt M, Krupka K, et al. Age-Related Differences in Rejection Rates, Infections, and Tacrolimus Exposure in Pediatric Kidney Transplant Recipients in the CERTAIN Registry. Kidney Int Rep. 2024. PMID: 39534206. doi:10.1016/j.ekir.2024.08.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。